Disease duration varied across subtypes; notably, PiD (mean ~ 11 years) and FTLD-TDP type C (mean ~ 9 years) had longer survival, while other tauopathies (mean ~ 6 years) and FTLD-TDP type B (mean ~ 6 years) and type E (mean ~ 2.5 years) had shorter disease duration. This evidence concerns the gene MTA2 and tauopathy.